The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of ActionMarkus Joerger, Martin Früh, Thomas Cerny et al.|Current Drug Targets|2009Cited by 48
557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trialPatrizia Froesch, Martin Früh, Michael Mark et al.|Annals of Oncology|2020Cited by 1